DOCSLIB.ORG

Ramucirumab: a New Therapy for Advanced Gastric Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ramucirumab: a New Therapy for Advanced Gastric Cancer PRESCRIBER'S CORNER Section Editors: Christopher J. Campen and Beth Eaby-Sandy Ramucirumab: A New Therapy for Advanced Gastric Cancer ANDREA LANDGRAF OHOLENDT, PharmD, BCOP, and JENNIFER L. ZADLO, PharmD, BCOP From The University of Texas MD Anderson astric cancer is the fourth a third agent, which is typically epi- Cancer Center, Houston, Texas most common cancer in rubicin or docetaxel. Two-drug regi- Authors’ disclosures of potential conflicts of interest are found at the end of this article. men and the fifth most mens are generally preferred, since Correspondence to: Andrea Landgraf Oholendt, common cancer in wom- they are associated with less toxic- PharmD, BCOP, The University of Texas MD Gen worldwide (Jemal et al., 2011). ity (National Comprehensive Cancer Anderson Cancer Center, Division of Pharmacy, The American Cancer Society (ACS) Network [NCCN], 2014). 1515 Holcombe Boulevard, FC6.3002, Unit 90, Houston, TX 77030. has estimated there were 22,220 new Prior to 2014, there were no cate- E-mail: [email protected] cases diagnosed in 2014, with an es- gory 1 recommendations for second- © 2015 Harborside Press® timated 10,990 deaths (Siegel, Ma, line therapy for gastric cancer. The Zou, & Jemal, 2014). Despite some decision to give second-line therapy advances in treatment, gastric can- was generally based on the patient’s cer continues to be associated with performance status and prior ther- poor outcomes. apy exposure. Preferred regimens Approximately two-thirds of pa- included single-agent irinotecan tients diagnosed with gastric cancer or taxane (docetaxel or paclitaxel; have locally advanced or metastatic NCCN, 2014). The development of disease, with a median survival of new therapies offers viable treat- around 10 months (Chau et al., 2004). ment options for patients with ad- Chemotherapy is the primary modal- vanced and metastatic disease. ity for management of advanced and metastatic gastric cancers and has ANGIOGENESIS been shown to improve quality of life Angiogenesis is an important and prolong survival (Wagner et al., process in cancer development and 2006). The standard of care for treat- growth. Angiogenesis is primarily ment of advanced disease is poorly driven by the interactions between defined, with no preferred first- or vascular endothelial growth factor second-line regimens. (VEGF) ligands and VEGF recep- Category 1 recommendations for tors (VEGFRs). The VEGF ligands first-line therapy for locally advanced include VEGF-A, VEGF-B, VEGF- and metastatic disease include a two- C, VEGF-D, VEGF-E, and placental drug regimen of cisplatin combined growth factor (PGF; Claesson-Welsh with a fluoropyrimidine (fluoroura- & Welsh, 2013). Overexpression cil or capecitabine) or cisplatin and of VEGF has been associated with J Adv Pract Oncol 2015;6:71–75 a fluoropyrimidine combined with advanced-stage disease and poor- 71 PRESCRIBER'S CORNER LANDGRAF OHOLENDT and ZADLO er outcomes and prognosis in gastric cancer A total of 238 patients received ramucirum- (Maeda et al., 1996). ab intravenously (IV) at a dose of 8 mg/kg every Bevacizumab (Avastin) was the first antian- 2 weeks, and 117 patients were randomized to giogenic agent approved by the US Food and Drug the placebo arm. The study investigators found a Administration (FDA) and exerts its effect by pre- statistically significant difference in the primary venting the binding of the VEGF-A ligand to its re- endpoint, median overall survival (OS). Patients ceptors. However, a phase III clinical trial did not who received ramucirumab plus BSC had a longer demonstrate a significant improvement in overall median OS, 5.2 months (range, 2.3–9.9 months), survival when adding bevacizumab to chemother- than did patients who received placebo plus BSC, apy for first-line treatment of advanced gastric 3.8 months (1.7–7.1 months); the hazard ratio was cancer (Ohtsu et al., 2011). 0.776 (95% confidence interval [CI], 0.603–0.998), Ramucirumab (Cyramza) is the first FDA- and the p value was .047. Of note, the longer me- approved agent to reduce tumor angiogenesis by dian OS in the ramucirumab arm was preserved targeting the extracellular domain of the VEGFR. when repeated with multivariate analysis (p = It remains unclear why ramucirumab has demon- .037; Fuchs et al., 2014). strated efficacy for advanced gastric cancer while Progression free survival (PFS) was also lon- bevacizumab demonstrated mixed results. One ger with ramucirumab plus BSC (2.1 months; rationale is ramucirumab blocks VEGFR-2, the range, 1.3–4.2 months) than with placebo plus primary receptor for VEGF-A, rather than block- BCS (1.3 months; range, 1.1–2.1 months); the haz- ing the ligand itself (Park, Thomas, Yoon, & Yoon, ard ratio was 0.483 (95% CI, 0.376–0.620), and the 2015; Spratlin, Mulder, & Mackey, 2010). p value was < .0001. Also statistically significant was an increased disease control rate of 49% with MECHANISM OF ACTION ramucirumab plus BSC, compared with 23% with Ramucirumab is a recombinant human immu- placebo plus BSC. noglobulin G1 monoclonal antibody that binds to Best response was modest at best, typically the extracellular binding domain of VEGFR-2 and stable disease (SD), which was seen in 45% of prevents the binding of VEGFR ligands: VEGF-A, patients (n = 108) who received ramucirumab VEGF-C, and VEGF-D (Eli Lilly and Company, plus BSC, and 21% of patients who received pla- 2014; Wadhwa, Taketa, Sudo, Blum-Murphy, & cebo plus BSC (n = 24). Only one patient achieved Ajani, 2013). Through blocking activation of VEG- a complete response, and seven patients (3%) FR-2 by VEGF-A and the other VEGF ligands, achieved a partial response with ramucirum- ramucirumab inhibits the angiogenesis pathways ab plus BSC. Disease progressed in all others involved in the development and progression of (Fuchs et al., 2014). gastric cancer. This study also included a 6-week quality-of- life assessment (QOL), to which data were avail- CLINICAL STUDIES able in 48% and 25% of the patients who received To date, there are two studies evaluating ramucirumab plus BSC and placebo plus BSC, the efficacy of ramucirumab for the treatment respectively. Although not statistically significant of gastric and gastroesophageal (GE) junction (p = .23), there was a trend toward stable or improved adenocarcinoma. The REGARD trial was an in- global QOL reported in patients who received ternational, prospective, double-blind, placebo- ramucirumab plus BSC. There was, however, a sta- controlled, phase III study in adult patients with tistically significant longer time to deterioration advanced or metastatic gastric or GE junction ad- in Eastern Cooperative Oncology Group (ECOG) enocarcinoma. Those patients who failed to re- performance status to a score of ≥ 2 in patients spond to a first-line platinum or fluoropyrimidine- who received ramucirumab plus BSC (5.1 months) containing regimen were randomized in a 2:1 compared with placebo plus BSC (2.4 months; fashion to receive either ramucirumab plus p = .002; Fuchs et al., 2014). best supportive care (BSC) or placebo plus BSC The RAINBOW trial was the second study (Fuchs et al., 2014). to evaluate the efficacy of ramucirumab. The 72 RAMUCIRUMAB PRESCRIBER'S CORNER RAINBOW trial was an international, placebo- As demonstrated in Tables 1 and 2, the adverse controlled, randomized, double-blind, phase drug reaction profile varied when ramucirumab III study of patients with advanced, nonresect- was used as monotherapy vs. in combination with able GE junction or gastric adenocarcinoma that paclitaxel. Because of its antiangiogenic activity, had progressed within 4 months of receiving a concern for serious antiangiogenic adverse drug first-line platinum and fluoropyrimidine-based reactions, including GI perforations, impaired chemotherapy regimen. Patients were ran- wound healing, venous and arterial thrombo- domized to receive ramucirumab at a dose of 8 embolism, and hemorrhage, should be applied. mg/kg IV on days 1 and 15 plus paclitaxel 80 Ramucirumab is currently labeled with a Boxed mg/m2 IV on days 1, 8, and 15 of a 28-day cycle or Warning for hemorrhage and serious bleeding placebo plus paclitaxel 80 mg/m2 IV on days 1, 8, events; however, the incidence of bleeding/hem- and 15 of a 28-day cycle; crossover was prohib- orrhage was similar between ramucirumab and ited. A total of 665 patients were randomized; placebo in the REGARD trial. 330 patients received ramucirumab plus pacli- Although ramucirumab is a recombinant hu- taxel and 335 received placebo plus paclitaxel man monoclonal antibody, infusion-related re- (Wilke et al., 2014). actions have been reported in clinical studies. This study found a statistically significant dif- Therefore, premedication with an IV histamine ference in the primary endpoint of median OS, (H1) antagonist is recommended by the manufac- which was longer in patients who received ramu- turer (Fuchs et al., 2014; Wilke et al., 2014; Eli Lilly cirumab plus paclitaxel (9.6 months) than in those and Company, 2014). who received placebo plus paclitaxel (7.4 months; hazard ratio = 0.807; 95% CI, 0.678–0.962; p = DOSING .017). Improvements in median PFS were also Based on the clinical data presented, ramu- observed with ramucirumab plus paclitaxel (4.4 cirumab is dosed at 8 mg/kg, using actual body months) vs. placebo plus paclitaxel (2.86 months; weight, IV over 60 minutes, every 2 weeks. Cur- p < .0001). A majority of patients achieved SD: 52% rently, ramucirumab is approved by the FDA in in the ramucirumab plus paclitaxel arm vs. 47% in the second-line setting for patients with gastric the paclitaxel plus placebo arm. or GE junction adenocarcinoma, as monotherapy Partial response and complete response were or in combination with paclitaxel, and continued achieved in 27% and < 1%, respectively, of those until disease progression or unacceptable toxicity who received ramucirumab plus paclitaxel com- (Eli Lilly and Company, 2014). pared with 16% and < 1%, respectively, of those who received paclitaxel plus placebo.
Load more

Recommended publications
  • USAN Naming Guidelines for Monoclonal Antibodies |
    Monoclonal Antibodies In October 2008, the International Nonproprietary Name (INN) Working Group Meeting on Nomenclature for Monoclonal Antibodies (mAb) met to review and streamline the monoclonal antibody nomenclature scheme. Based on the group's recommendations and further discussions, the INN Experts published changes to the monoclonal antibody nomenclature scheme. In 2011, the INN Experts published an updated "International Nonproprietary Names (INN) for Biological and Biotechnological Substances—A Review" (PDF) with revisions to the monoclonal antibody nomenclature scheme language. The USAN Council has modified its own scheme to facilitate international harmonization. This page outlines the updated scheme and supersedes previous schemes. It also explains policies regarding post-translational modifications and the use of 2-word names. The council has no plans to retroactively change names already coined. They believe that changing names of monoclonal antibodies would confuse physicians, other health care professionals and patients. Manufacturers should be aware that nomenclature practices are continually evolving. Consequently, further updates may occur any time the council believes changes are necessary. Changes to the monoclonal antibody nomenclature scheme, however, should be carefully considered and implemented only when necessary. Elements of a Name The suffix "-mab" is used for monoclonal antibodies, antibody fragments and radiolabeled antibodies. For polyclonal mixtures of antibodies, "-pab" is used. The -pab suffix applies to polyclonal pools of recombinant monoclonal antibodies, as opposed to polyclonal antibody preparations isolated from blood. It differentiates polyclonal antibodies from individual monoclonal antibodies named with -mab. Sequence of Stems and Infixes The order for combining the key elements of a monoclonal antibody name is as follows: 1.
    [Show full text]
  • Monoclonal Antibody Playbook
    Federal Response to COVID-19: Monoclonal Antibody Clinical Implementation Guide Outpatient administration guide for healthcare providers 2 SEPTEMBER 2021 1 Introduction to COVID-19 Monoclonal Antibody Therapy 2 Overview of Emergency Use Authorizations 3 Site and Patient Logistics Site preparation Patient pathways to monoclonal administration 4 Team Roles and Responsibilities Leadership Administrative Clinical Table of 5 Monoclonal Antibody Indications and Administration Indications Contents Preparation Administration Response to adverse events 6 Supplies and Resources Infrastructure Administrative Patient Intake Administration 7 Examples: Sites of Administration and Staffing Patterns 8 Additional Resources 1 1. Introduction to Monoclonal Therapy 2 As of 08/13/21 Summary of COVID-19 Therapeutics 1 • No Illness . Health, no infections • Exposed Asymptomatic Infected . Scope of this Implementation Guide . Not hospitalized, no limitations . Monoclonal Antibodies for post-exposure prophylaxis (Casirivimab + Imdevimab (RGN)) – EUA Issued. • Early Symptomatic . Scope of this Implementation Guide . Not hospitalized, with limitations . Monoclonal Antibodies for treatment (EUA issued): Bamlanivimab + Etesevimab1 (Lilly) Casirivimab + Imdevimab (RGN) Sotrovimab (GSK/Vir) • Hospital Adminission. Treated with Remdesivir (FDA Approved) or Tocilizumab (EUA Issued) . Hospitalized, no acute medical problems . Hospitalized, not on oxygen . Hospitlaized, on oxygen • ICU Admission . Hospitalized, high flow oxygen, non-invasive ventilation
    [Show full text]
  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2017 (February 9, 2017) REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) New York 000-19034 13-3444607 (State or other jurisdiction (Commission (IRS Employer of Incorporation) File No.) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices, including zip code) (914) 847-7000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 2.02 Results of Operations and Financial Condition. On February 9, 2017, Regeneron Pharmaceuticals, Inc. issued a press release announcing its financial and operating results for the quarter and year ended December 31, 2016. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02.
    [Show full text]
  • The Future of Antibodies As Cancer Drugs
    REVIEWS Drug Discovery Today Volume 17, Numbers 17/18 September 2012 The biopharmaceutical industry’s pipeline of anticancer antibodies includes 165 candidates with substantial diversity in composition, targets and mechanisms of action that hold promise to be the cancer drugs of the future. Reviews FOUNDATION REVIEW Foundation review: The future of antibodies as cancer drugs 1 2 Dr Janice Reichert Janice M. Reichert and Eugen Dhimolea is Research Assistant Professor at Tufts 1 Center for the Study of Drug Development, Tufts University School of Medicine, 75 Kneeland Street, University’s Center for the Study of Drug Development Suite 1100, Boston, MA 02111, USA 2 (CSDD). She is also Founder Department of Medical Oncology, Dana-Farber Cancer Institute/Harvard Medical School, 77 Louis Pasteur Ave., and Editor-in-Chief of mAbs, Harvard Institutes of Medicine, Room 309, Boston, MA 02215, USA a peer-reviewed, PubMed- indexed biomedical journal that focuses on topics relevant to antibody research Targeted therapeutics such as monoclonal antibodies (mAbs) have proven and development; President of the board of directors of The Antibody Society; and a member of the board successful as cancer drugs. To profile products that could be marketed in of the Peptide Therapeutics Foundation. At CSDD, the future, we examined the current commercial clinical pipeline of mAb Dr Reichert studies innovation in the pharmaceutical and biotechnology industries. Her work focuses on candidates for cancer. Our analysis revealed trends toward development of strategic analyses of investigational candidates and marketed products, with an emphasis on the clinical a variety of noncanonical mAbs, including antibody–drug conjugates development and approval of new therapeutics and (ADCs), bispecific antibodies, engineered antibodies and antibody vaccines.
    [Show full text]
  • CYRAMZA (Ramucirumab) Injection Label
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION • 500 mg/50 mL (10 mg per mL) solution, single-dose vial (3) These highlights do not include all the information needed to use CYRAMZA safely and effectively. See full prescribing information ------------------------------- CONTRAINDICATIONS ------------------------------ for CYRAMZA. None CYRAMZA (ramucirumab) injection, for intravenous infusion ------------------------ WARNINGS AND PRECAUTIONS ----------------------- Initial U.S. Approval: 2014 • Arterial Thromboembolic Events (ATEs): Serious, sometimes fatal WARNING: HEMORRHAGE ATEs have been reported in clinical trials. Discontinue CYRAMZA for severe ATEs. (5.2) See full prescribing information for complete boxed warning. • Hypertension: Monitor blood pressure and treat hypertension. CYRAMZA increased the risk of hemorrhage, including severe Temporarily suspend CYRAMZA for severe hypertension. and sometimes fatal hemorrhagic events. Permanently Discontinue CYRAMZA for hypertension that cannot be medically discontinue CYRAMZA in patients who experience severe controlled. (5.3) bleeding [see Dosage and Administration (2.3), Warnings and • Infusion-Related Reactions: Monitor for signs and symptoms Precautions (5.1)]. during infusion. (5.4) • Gastrointestinal Perforation: Discontinue CYRAMZA. (5.5) --------------------------- RECENT MAJOR CHANGES -------------------------- • Impaired Wound Healing: Withhold CYRAMZA prior to surgery. Indications and Usage 11/2014 (5.6) • Clinical Deterioration in Patients with Cirrhosis: New onset or Dosage and Administration:
    [Show full text]
  • COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody
    Review Article ISSN: 2574 -1241 DOI: 10.26717/BJSTR.2020.29.004828 COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody Basma H Marghani* Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt *Corresponding author: Basma H Marghani, Department of Physiology, Faculty of Veterinary Medicine, Mansoura University, Egypt ARTICLE INFO ABSTRACT Received: August 10, 2020 Published: August 18, 2020 rapidly to the other countries all over the world, caused a novel Coronavirus-2019 (COV- SARS-CoV-2 was appeared firstly in Wuhan, China in December 2019, then spread- gency. After infection, virus entry the host cell through spike proteins (S)- angiotensin Citation: Basma H Marghani. COVID-19 ID-19). The World Health Organization was branded COVID-19 as a global health emer Immunotherapy: Novel Humanized 47D11 converting enzyme 2 (ACE2) cell membrane receptor via their S-Binding domain, then Monoclonal Antibody. Biomed J Sci & Tech virus replication caused acute respiratory disease syndrome (ARDS). Till now there was Res 29(4)-2020. BJSTR. MS.ID.004828. no vaccines or anti-viral drugs for coronavirus infection. One effective treatment is the use of human monoclonal antibodies (mAbs) which are engineered to target and block Keywords: COVID-19; Immunotherapy; cell surface receptor. mAbs could be given to people in the early stages of COVID-19 as a Full-Length Humanized Monoclonal Anti- therapeutic, or used prophylactically to give immediate, long-term immunity to vulnera- bodies; ACE Inhibitor ble people such as healthcare workers. The neutralizing humanized 47D11 monoclonal antibody targets a common epitope on SARS-CoV2 virus and may offer potential for pre- Abbreviations: ACE2: Angiotensin-Con- vention and treatment of COVID-19.89U (Graphical Abstract 1).
    [Show full text]
  • Erbitux® (Cetuximab)
    Erbitux® (cetuximab) (Intravenous) -E- Document Number: MODA-0494 Last Review Date: 06/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 06/2021 I. Length of Authorization 1 Coverage will be provided for six months and may be renewed unless otherwise specified. • SCCHN in combination with radiation therapy: Coverage will be provided for the duration of radiation therapy (6-7 weeks). II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: Weekly Every two weeks Erbitux 100 mg/50 mL solution for injection 1 vial every 7 days 1 vial every 14 days 3 vials every 7 days Erbitux 200 mg/100 mL solution for injection 6 vials every 14 days (5 vials for first dose only) B. Max Units (per dose and over time) [HCPCS Unit]: Weekly Every two weeks − Load: 100 billable units x 1 dose 120 billable units every 14 days − Maintenance Dose: 60 billable units every 7 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Colorectal Cancer (CRC) † ‡ 1,2,12,13,17,19,2e,5e-8e,10e-12e,15e • Patient is both KRAS and NRAS mutation negative (wild-type) as determined by FDA- approved or CLIA-compliant test*; AND • Will not be used as part of an adjuvant treatment regimen; AND • Patient has not been previously treated with cetuximab or panitumumab; AND • Will not be used in combination with an anti-VEGF agent (e.g., bevacizumab, ramucirumab); AND Moda Health Plan, Inc.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • The Angiopoietin-2 and TIE Pathway As a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer
    International Journal of Molecular Sciences Review The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer Alessandra Leong and Minah Kim * Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USA; afl[email protected] * Correspondence: [email protected] Received: 26 September 2020; Accepted: 13 November 2020; Published: 18 November 2020 Abstract: Despite significant advances made in cancer treatment, the development of therapeutic resistance to anticancer drugs represents a major clinical problem that limits treatment efficacy for cancer patients. Herein, we focus on the response and resistance to current antiangiogenic drugs and immunotherapies and describe potential strategies for improved treatment outcomes. Antiangiogenic treatments that mainly target vascular endothelial growth factor (VEGF) signaling have shown efficacy in many types of cancer. However, drug resistance, characterized by disease recurrence, has limited therapeutic success and thus increased our urgency to better understand the mechanism of resistance to inhibitors of VEGF signaling. Moreover, cancer immunotherapies including immune checkpoint inhibitors (ICIs), which stimulate antitumor immunity, have also demonstrated a remarkable clinical benefit in the treatment of many aggressive malignancies. Nevertheless, the emergence of resistance to immunotherapies associated with an immunosuppressive tumor microenvironment has restricted therapeutic response, necessitating the development of better therapeutic strategies to increase treatment efficacy in patients. Angiopoietin-2 (ANG2), which binds to the receptor tyrosine kinase TIE2 in endothelial cells, is a cooperative driver of angiogenesis and vascular destabilization along with VEGF. It has been suggested in multiple preclinical studies that ANG2-mediated vascular changes contribute to the development and persistence of resistance to anti-VEGF therapy.
    [Show full text]
  • Cyramza® (Ramucirumab)
    Cyramza® (ramucirumab) (Intravenous) -E- Document Number: MODA-0405 Last Review Date: 07/01/2021 Date of Origin: 09/03/2019 Dates Reviewed: 09/2019, 10/2019, 01/2020, 04/2020, 07/2020, 10/2020, 01/2021, 04/2021, 07/2021 I. Length of Authorization Coverage will be provided for 6 months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: • Cyramza 100 mg/10 mL: 4 vials per 14 days • Cyramza 500 mg/50 mL: 2 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: Gastric, Gastroesophageal, HCC, and Colorectal Cancer: • 180 billable units every 14 days NSCLC: • 240 billable units every 14 days III. Initial Approval Criteria 1 Coverage is provided in the following conditions: • Patient is at least 18 years of age; AND Universal Criteria 1 • Patient does not have uncontrolled severe hypertension; AND • Patient must not have had a surgical procedure within the preceding 28 days or have a surgical wound that has not fully healed; AND Gastric, Esophageal, and Gastro-esophageal Junction Adenocarcinoma † Ф 1-3,5-7,14,17,2e,5e • Used as subsequent therapy after fluoropyrimidine- or platinum-containing chemotherapy; AND • Used as a single agent OR in combination with paclitaxel; AND o Used for one of the following: Moda Health Plan, Inc. Medical Necessity Criteria Page 1/27 Proprietary & Confidential © 2021 Magellan Health, Inc. – Patient has unresectable locally advanced, recurrent, or metastatic disease; OR – Used as palliative therapy for locoregional disease in patients who are not surgical candidates
    [Show full text]
  • Coverage of Monoclonal Antibody Products to Treat COVID-19
    Coverage of Monoclonal Antibody Products to Treat COVID-19 Monoclonal antibody products to treat Coronavirus disease 2019 (COVID-19) help the body fight the virus or slow the virus’s growth. Medicare beneficiaries have coverage without beneficiary cost sharing for these products when used as authorized or approved by the Food and Drug Administration (FDA). Disclaimer: The contents of this document do not have the force and effect of law and are not meant to bind the public Medicare in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. This communication was printed, published, or produced and disseminated at U.S. taxpayer expense. Site of Care1 Payable by Expected Patient Expected Payment to Providers: Medicare Cost-Sharing Key Facts • Medicare payment for monoclonal antibody products to treat COVID-19 is similar across Inpatient No patient sites of care, with some small differences. Hospital cost-sharing • Medicare pays for the administration of monoclonal antibody products to treat COVID-19. For example, beginning on May 6, 2021, Medicare will pay approximately Outpatient $450 in most settings, or approximately $750 No patient in the beneficiary’s home or residence, for Hospital or cost-sharing the administration of certain monoclonal “Hospital 4 2 antibody products to treat COVID-19. For without Walls ” monoclonal antibody products to treat COVID-19 that are administered before May 6, 2021, the Medicare payment rate in all No patient settings is approximately $310. Outpatient cost-sharing3 Physician Office/ • CMS will exercise enforcement discretion to Infusion Center allow Medicare-enrolled immunizers working within their scope of practice and subject to applicable state law to bill directly and receive direct reimbursement from the Medicare program for administering Nursing Home monoclonal antibody treatments to No patient (See third bullet in Medicare Part A Skilled Nursing Facility Key Facts on CMS cost-sharing residents.
    [Show full text]
  • An EANM Procedural Guideline
    European Journal of Nuclear Medicine and Molecular Imaging https://doi.org/10.1007/s00259-018-4052-x GUIDELINES Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline A. Signore1 & F. Jamar2 & O. Israel3 & J. Buscombe4 & J. Martin-Comin5 & E. Lazzeri6 Received: 27 April 2018 /Accepted: 6 May 2018 # The Author(s) 2018 Abstract Introduction Radiolabelled autologous white blood cells (WBC) scintigraphy is being standardized all over the world to ensure high quality, specificity and reproducibility. Similarly, in many European countries radiolabelled anti-granulocyte antibodies (anti-G-mAb) are used instead of WBC with high diagnostic accuracy. The EANM Inflammation & Infection Committee is deeply involved in this process of standardization as a primary goal of the group. Aim The main aim of this guideline is to support and promote good clinical practice despite the complex environment of a national health care system with its ethical, economic and legal aspects that must also be taken into consideration. Method After the standardization of the WBC labelling procedure (already published), a group of experts from the EANM Infection & Inflammation Committee developed and validated these guidelines based on published evidences. Results Here we describe image acquisition protocols, image display procedures and image analyses as well as image interpre- tation criteria for the use of radiolabelled WBC and monoclonal antigranulocyte antibodies. Clinical application for WBC and anti-G-mAb scintigraphy is also described. Conclusions These guidelines should be applied by all nuclear medicine centers in favor of a highly reproducible standardized practice. Keywords Infection .
    [Show full text]